Hormone replacement with estradiol: Conventional oral doses result in excessive exposure to estrone

Alternative Medicine Review

Volumn 10, Issue 1, 2005, Pages 36-41

  Friel, Patrick N ^a,b   Hinchcliffe, Christa ^c   Wright, Jonathan V ^c  

^a Meridian Valley Laboratory   (United States)

^b Tahoma Clinic ^*  (United States)

^c Tahoma Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRIOL; ESTRONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; DRUG EXPOSURE; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; POSTMENOPAUSE; PREMENOPAUSE; RETROSPECTIVE STUDY; URINARY EXCRETION; URINE LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ESTRADIOL; ESTRIOL; ESTRONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 15444378345     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
2. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
3. Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003;88:1394-1399.
4. Wiseman RA. Breast cancer: critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly. J Clin Epidemiol 2004;57:766-772.
5. Wren BG. Do female sex hormones initiate breast cancer? A review of the evidence. Climacteric 2004;7:120-128.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
8. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
9. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762.
10. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002;177:347-351.
11. HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?): a randomized comparison trial stopped. Obstet Gynecol Surv 2004;59:442-443.
12. Burtis CA. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: W.B. Saunders Company. 1999.
13. Tepper R, Goldberger S, Cohen I, et al. Estrogen replacement in postmenopausal women: are we currently overdosing our patients? Gynecol Obstet Invest 1994;38:113-116.
14. Coelingh Bennink HJ. Are all estrogens the same? Maturitas 2004;47:269-275.
15. Alvarez-Vasquez RB, Axelrod D, Frenkel K, et al. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer. Horm Metab Res 2003;35:358-361.
16. Adlercreutz H, Gorbach SL, Goldin BR, et al. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 1994;86:1076-1082.
17. Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung 2003;53:1-11.
18. Ursin G, Palla SL, Reboussin BA, et al. Posttreatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. J Clin Oncol 2004;22:2842-2848.
19. Stehman-Breen C, Anderson G, Gibson D, et al. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int 2003;64:290-294.
20. Estrone RIA Package Insert, DSL-8700, Diagnostic Systems Laboratories, Inc. 1999.
21. Cohen JS. Over Dose: The Case Against the Drug Companies. New York, NY: Penguin Putnam; 2001.
22. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-1048.
23. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451.
24. Melamed M, Castano E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/ antagonist activity of estriol. Mol Endocrinol 1997;11:1868-1878.
25. Siiteri PK, Sholtz RI, Cirillo PM, et al. Prospective study of estrogens during pregnancy and risk of breast cancer. http://cdmrp.army.mil/bcrp/era/ abstracts2002/p13_chemoprevention/9919358_abs. pdf
26. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
27. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-3263.